Citizens maintained its Market Outperform rating on Stereotaxis with a $4.00 price target, citing a compelling razor/razor blade ecosystem as a driver of sustainable growth. Analyst Daniel Stauder pointed to developing tailwinds for system adoption and improved procedural utilization through 2026 and into 2027. The $4.00 target is based on an EV/revenue multiple of roughly 6x to 7x applied to a 2027 total sales estimate of $53 million, a premium multiple the firm considers reasonable given an expected approximately 30% top-line growth profile. Stereotaxis reported first-quarter 2026 revenue of $6.3 million, down from $7.5 million a year earlier, with recurring revenue pressured by the wind-down of its legacy Johnson & Johnson catheter relationship. The company ended the quarter with $14.6 million in cash and no debt, and noted that demand for its MAGiC cardiac ablation catheter far exceeds current supply.
Stereotaxis IncDemand for MAGiC catheter far exceeds supply, and analyst sees razor/razor blade ecosystem driving growth.
Johnson & JohnsonWind-down of legacy Johnson & Johnson catheter relationship pressured Stereotaxis' recurring revenue.